Literature DB >> 22573798

Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey.

V Paul Doria-Rose1, Mary C White, Carrie N Klabunde, Marion R Nadel, Thomas B Richards, Timothy S McNeel, Juan L Rodriguez, Pamela M Marcus.   

Abstract

BACKGROUND: Before evidence of efficacy, lung cancer screening was being ordered by many physicians. The National Lung Screening Trial (NLST), which showed a 20% reduction in lung cancer mortality among those randomized to receive low-dose computed tomography (LDCT), will likely lead to increased screening use.
METHODS: We estimated the prevalence of chest X-ray and CT use in the United States using data from the 2010 National Health Interview Survey (NHIS). Subjects included 15,537 NHIS respondents aged ≥40 years without prior diagnosis of lung cancer. Estimates of the size of the U. S. population by age and smoking status were calculated. Multivariate logistic regression examined predictors of test use adjusting for potential confounders.
RESULTS: Twenty-three percent of adults reported chest X-ray in the previous year and 2.5% reported chest X-ray specifically to check for lung cancer; corresponding numbers for chest CT were 7.5% and 1.3%. Older age, black race, male gender, smoking, respiratory disease, personal history of cancer, and having health insurance were associated with test use. Approximately, 8.7 million adults in the United States would be eligible for LDCT screening according to NLST eligibility criteria. CONCLUSIONS AND IMPACT: Monitoring of trends in the use of lung screening tests will be vital to assess the impact of NLST and possible changes in lung cancer screening recommendations and insurance coverage in the future. Education of patients by their physicians, and of the general public, may help ensure that screening is used appropriately, in those most likely to benefit. ©2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 22573798      PMCID: PMC3392469          DOI: 10.1158/1055-9965.EPI-12-0343

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Lung cancer screening: ready for prime time?

Authors:  Judy Peres
Journal:  J Natl Cancer Inst       Date:  2010-12-29       Impact factor: 13.506

2.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries.

Authors:  Dik Habbema; Inge M C M De Kok; Martin L Brown
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

3.  Summary health statistics for U.S. adults: National Health Interview Survey, 2010.

Authors:  Jeannine S Schiller; Jacqueline W Lucas; Brian W Ward; Jennifer A Peregoy
Journal:  Vital Health Stat 10       Date:  2012-01

4.  Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Authors:  Martin M Oken; Willam G Hocking; Paul A Kvale; Gerald L Andriole; Saundra S Buys; Timothy R Church; E David Crawford; Mona N Fouad; Claudine Isaacs; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Joshua M Rathmell; Thomas L Riley; Patrick Wright; Neil Caparaso; Ping Hu; Grant Izmirlian; Paul F Pinsky; Philip C Prorok; Barnett S Kramer; Anthony B Miller; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-10-26       Impact factor: 56.272

Review 5.  Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.

Authors:  Stephen Feig
Journal:  Radiol Clin North Am       Date:  2010-09       Impact factor: 2.303

6.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

7.  Lung cancer screening practices of primary care physicians: results from a national survey.

Authors:  Carrie N Klabunde; Pamela M Marcus; Paul K J Han; Thomas B Richards; Sally W Vernon; Gigi Yuan; Gerard A Silvestri
Journal:  Ann Fam Med       Date:  2012 Mar-Apr       Impact factor: 5.166

8.  Cost-effectiveness of computed tomography screening for lung cancer in the United States.

Authors:  Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

9.  Utilization of surveillance colonoscopy in community practice.

Authors:  Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Douglas J Reding; Richard B Hayes; Timothy Church; Susan Yurgalevich; V Paul Doria-Rose; Tom Hickey; Thomas Riley; Christine D Berg
Journal:  Gastroenterology       Date:  2009-10-08       Impact factor: 22.682

Review 10.  Cost-effectiveness of colorectal cancer screening.

Authors:  Iris Lansdorp-Vogelaar; Amy B Knudsen; Hermann Brenner
Journal:  Epidemiol Rev       Date:  2011-06-01       Impact factor: 6.222

View more
  36 in total

1.  Current Smokers' Preferences for Receiving Cessation Information in a Lung Cancer Screening Setting.

Authors:  Lisa Carter-Harris; Rhonda Schwindt; Giorgos Bakoyannis; DuyKhanh Pham Ceppa; Susan M Rawl
Journal:  J Cancer Educ       Date:  2018-10       Impact factor: 2.037

2.  Pulmonary nodule classification in lung cancer screening with three-dimensional convolutional neural networks.

Authors:  Shuang Liu; Yiting Xie; Artit Jirapatnakul; Anthony P Reeves
Journal:  J Med Imaging (Bellingham)       Date:  2017-11-14

3.  Lung Cancer Field Cancerization: Implications for Screening by Low-Dose Computed Tomography.

Authors:  Ana I Robles; Curtis C Harris
Journal:  J Natl Cancer Inst       Date:  2017-07-01       Impact factor: 13.506

4.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015.

Authors:  Ahmedin Jemal; Stacey A Fedewa
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

5.  Sputum-based DNA methylation biomarkers to guide lung cancer screening decisions.

Authors:  Delphine Lissa; Ana I Robles
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  State-Level Variations in the Utilization of Lung Cancer Screening Among Medicare Fee-for-Service Beneficiaries: An Analysis of the 2015 to 2017 Physician and Other Supplier Data.

Authors:  Bian Liu; Kavita Dharmarajan; Claudia I Henschke; Emanuela Taioli
Journal:  Chest       Date:  2019-11-22       Impact factor: 9.410

7.  Lung Cancer Screening Inconsistent With U.S. Preventive Services Task Force Recommendations.

Authors:  Thomas B Richards; V Paul Doria-Rose; Ashwini Soman; Carrie N Klabunde; Ralph S Caraballo; Simone C Gray; Keisha A Houston; Mary C White
Journal:  Am J Prev Med       Date:  2018-11-19       Impact factor: 5.043

8.  Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening.

Authors:  Fabrice Smieliauskas; Heber MacMahon; Ravi Salgia; Ya-Chen Tina Shih
Journal:  J Med Screen       Date:  2014-08-12       Impact factor: 2.136

9.  Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening.

Authors:  David H Howard; Thomas B Richards; Peter B Bach; Michelle C Kegler; Carla J Berg
Journal:  Cancer       Date:  2015-09-15       Impact factor: 6.860

10.  Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Lung Cancer       Date:  2016-06-14       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.